Valiant Organics Ltd
Incorporated in 1984, Valiant Organics
Ltd manufactures and deals in specialty chemicals and pharma intermediates[1]
- Market Cap ₹ 983 Cr.
- Current Price ₹ 351
- High / Low ₹ 508 / 225
- Stock P/E 195
- Book Value ₹ 236
- Dividend Yield 0.00 %
- ROCE 2.97 %
- ROE -0.45 %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 4.25% over past five years.
- Company has a low return on equity of 3.12% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Part of BSE SmallCap BSE Allcap BSE Commodities
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
43 | 59 | 52 | 73 | 121 | 606 | 584 | 574 | 948 | 912 | 677 | 719 | 755 | |
34 | 48 | 36 | 55 | 94 | 426 | 410 | 417 | 783 | 782 | 638 | 665 | 692 | |
Operating Profit | 8 | 11 | 16 | 18 | 26 | 179 | 174 | 157 | 165 | 130 | 40 | 54 | 63 |
OPM % | 19% | 19% | 30% | 25% | 22% | 30% | 30% | 27% | 17% | 14% | 6% | 7% | 8% |
1 | 1 | 1 | 2 | 1 | 5 | 5 | 17 | 6 | 8 | 9 | 8 | 9 | |
Interest | 1 | 1 | 0 | 0 | 0 | 2 | 1 | 3 | 6 | 11 | 19 | 24 | 25 |
Depreciation | 1 | 1 | 1 | 2 | 2 | 12 | 13 | 19 | 27 | 28 | 34 | 36 | 36 |
Profit before tax | 8 | 11 | 16 | 18 | 25 | 171 | 165 | 152 | 137 | 100 | -5 | 2 | 10 |
Tax % | 32% | 34% | 35% | 35% | 35% | 29% | 25% | 25% | 25% | 24% | -41% | 224% | |
6 | 7 | 10 | 12 | 16 | 121 | 124 | 115 | 103 | 76 | -3 | -3 | 5 | |
EPS in Rs | 79.14 | 103.86 | 14.03 | 15.92 | 13.97 | 103.65 | 51.00 | 42.20 | 37.91 | 27.83 | -1.10 | -1.07 | 1.76 |
Dividend Payout % | 27% | 50% | 71% | 16% | 23% | 6% | 11% | 12% | 9% | 4% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 28% |
5 Years: | 4% |
3 Years: | -9% |
TTM: | 13% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 136% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | -21% |
3 Years: | -16% |
1 Year: | -11% |
Return on Equity | |
---|---|
10 Years: | 16% |
5 Years: | 9% |
3 Years: | 3% |
Last Year: | 0% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 0.36 | 0.36 | 4 | 4 | 6 | 6 | 12 | 27 | 27 | 27 | 28 | 28 |
Reserves | 18 | 21 | 19 | 42 | 53 | 254 | 374 | 475 | 576 | 638 | 637 | 634 |
5 | 8 | 1 | 1 | 1 | 53 | 119 | 150 | 306 | 220 | 216 | 212 | |
14 | 11 | 17 | 23 | 36 | 89 | 125 | 154 | 174 | 220 | 262 | 206 | |
Total Liabilities | 37 | 40 | 41 | 69 | 96 | 402 | 629 | 806 | 1,083 | 1,106 | 1,142 | 1,079 |
11 | 11 | 12 | 26 | 31 | 130 | 256 | 478 | 509 | 610 | 630 | 644 | |
CWIP | 0 | 1 | 0 | 0 | 0 | 66 | 129 | 46 | 110 | 70 | 86 | 66 |
Investments | 2 | 2 | 2 | 7 | 7 | 20 | 34 | 42 | 53 | 53 | 54 | 54 |
24 | 26 | 26 | 35 | 58 | 187 | 210 | 240 | 410 | 373 | 371 | 315 | |
Total Assets | 37 | 40 | 41 | 69 | 96 | 402 | 629 | 806 | 1,083 | 1,106 | 1,142 | 1,079 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
3 | 6 | 18 | 9 | 18 | 77 | 160 | 115 | -11 | 183 | 85 | 59 | |
-2 | -1 | -1 | -1 | -6 | -88 | -191 | -135 | -120 | -91 | -65 | -27 | |
-2 | -5 | -16 | -4 | -5 | 2 | 35 | 22 | 146 | -109 | -23 | -28 | |
Net Cash Flow | -2 | -0 | 0 | 4 | 7 | -8 | 5 | 1 | 14 | -17 | -3 | 4 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 90 | 74 | 71 | 88 | 112 | 73 | 69 | 74 | 97 | 85 | 113 | 88 |
Inventory Days | 94 | 42 | 36 | 97 | 44 | 45 | 47 | 85 | 58 | 69 | 91 | 71 |
Days Payable | 81 | 7 | 50 | 130 | 154 | 80 | 97 | 135 | 76 | 100 | 166 | 117 |
Cash Conversion Cycle | 103 | 110 | 57 | 55 | 2 | 37 | 20 | 25 | 80 | 54 | 38 | 43 |
Working Capital Days | 1 | 53 | 59 | 69 | 41 | 51 | 21 | 4 | 9 | 4 | -8 | -16 |
ROCE % | 43% | 43% | 61% | 52% | 48% | 91% | 41% | 27% | 18% | 12% | 1% | 3% |
Documents
Announcements
-
Appointment Of Secretarial Auditor
10h - Q1 FY26 unaudited results approved; profit Rs. 757.84L standalone, Rs. 820.28L consolidated; new secretarial auditor appointed.
-
Financial Results For The Quarter Ended June 30, 2025
10h - Q1 FY26 unaudited financial results approved; new secretarial auditor appointed for 5 years.
-
Board Meeting Outcome for Outcome Of Board Meeting For Approval Of Unaudited Financial Results For The Quarter Ended June 30, 2025
10h - Q1 FY26 unaudited financial results approved; secretarial auditor appointed for 5 years, subject to shareholder approval.
-
Board Meeting Intimation for Approval Of Financial Results For The Quarter Ended June 30, 2025.
7 Aug - Board meeting on Aug 13 to approve Q1 June 30, 2025 financial results and other business.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 9 Jul
Annual reports
Concalls
-
Jul 2025TranscriptNotesPPT
-
May 2025TranscriptNotesPPT
-
Feb 2025TranscriptNotesPPT
-
Dec 2024TranscriptNotesPPT
-
Aug 2024TranscriptNotesPPT
-
Jun 2024TranscriptNotesPPT
-
May 2024TranscriptNotesPPT
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT
-
Sep 2023Transcript PPT
-
Aug 2023TranscriptNotesPPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Nov 2022TranscriptNotesPPT
-
Sep 2022TranscriptNotesPPT
-
Aug 2022Transcript PPT
-
Jul 2022TranscriptNotesPPT
-
May 2022Transcript PPT
-
Mar 2022TranscriptNotesPPT
-
Mar 2022TranscriptNotesPPT
-
Feb 2022TranscriptNotesPPT
-
Sep 2021TranscriptNotesPPT
Business Overview:[1][2][3]
VOL is is promoted by Gogri, Chedda and Gala families. It manufactures specialty chemicals and is one of the largest manufacturers of chlorophenol derivatives, Benzene derivatives, PNA, PAP, Ortho Anisidine and Para Anisidine.
Product Portfolio[4]
1. Ammonolysis
Products include Para Nitro Aniline and Ortho Chloro Para Nitro Aniline, primarily serving the dyes and pigments industries.
2. Hydrogenation
The product range comprises Ortho Anisidine, Para Anisidine, IPPCA, Meta Chloro Aniline, Para Amino Phenol, and Ortho Amino Phenol, catering to dyes, pigments, pharmaceuticals, and agrochemicals sectors.
3. Chlorination
Key products are Para ChloroPhenol (PCP), Ortho ChloroPhenol (OCP), 2,4 Di ChloroPhenol (2,4 DCP), 2,6 Di ChloroPhenol (2,6 DCP), and 2,4,6 Tri ChloroPhenol (2,4,6 TCP), widely used in agrochemicals, cosmetics, veterinary, and pharmaceutical applications.